Newsroom

LATEST PUBLICATIONS

Performance Comparison of Illumina^® MiSeq™ and MiSeq™ i100 Systems using Invivoscribe’s LymphoTrack^® Assays

2026-04-20T09:00:11-07:00May 27th, 2025|

From prognostication to precision in acute myeloid leukemia

2025-05-08T16:47:49-07:00May 8th, 2025|

Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML

2025-05-09T09:20:30-07:00May 8th, 2025|

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina^® MiSeq^TM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

2026-01-07T13:13:14-08:00November 8th, 2024|

Performance Comparison of Invivoscribe’s LymphoTrack^® Assays Between Complete Genomics DNBSEQ-G99 and Illumina^® MiSeq^TM NGS Platforms

2026-04-20T09:02:18-07:00November 8th, 2024|

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

2025-08-26T07:35:25-07:00July 21st, 2023|

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

2025-12-19T18:08:11-08:00June 2nd, 2023|

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan

2025-12-29T12:29:29-08:00May 25th, 2023|

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

2023-05-11T03:12:47-07:00May 11th, 2023|

Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China

2023-02-23T06:28:40-08:00February 23rd, 2023|

AMP Europe

Jun 15-17, 2026
Tallin, Estonia
Attending
Visit Conference Website

27th Japanese Society for Laboratory Hematology

Jun 20 – 21, 2026
Naha, Japan
Exhibiting

The 30th Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer

Jun 30 – Jul 2, 2026
Hiroshima, Japan
Attending

33rd Japanese Society for Gene Diagnosis and Therapy

Jul 10 – 11, 2026
Fukuoka, Japan
Attending

CGC

Aug 1-5, 2026
Houston, TX
Exhibiting
Visit Conference Website

Newsroom

Newsroom

LATEST PUBLICATIONS

Performance Comparison of Illumina^® MiSeq™ and MiSeq™ i100 Systems using Invivoscribe’s LymphoTrack^® Assays

From prognostication to precision in acute myeloid leukemia

Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina^® MiSeq^TM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

Performance Comparison of Invivoscribe’s LymphoTrack^® Assays Between Complete Genomics DNBSEQ-G99 and Illumina^® MiSeq^TM NGS Platforms

LATEST PRESS

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China

CONFERENCES

AMP Europe

27th Japanese Society for Laboratory Hematology

The 30th Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer

33rd Japanese Society for Gene Diagnosis and Therapy

CGC

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD